Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS  H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR %[2]      Net sales5,2325,0474%4%6% Generics3,7363,7041%1%2% Biosimilars1,4961,34311%12%17%       ...